J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
Staying In Big Pharma
Executive Summary
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
You may also be interested in...
J&J Quits RSV Development With Two Rivals Already Poised For US Approval
The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Sanofi Gains New Innate Program In Expanded Collaboration
Deal Snapshot: Innate will receive €25m up front from Sanofi for an exclusive license to a new natural killer (NK) cell engager program and options to two additional targets.